Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | PREP | P48147 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | F13A1 | P00488 | 1/20 | 0.35 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | TGM1 | P22735 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26906132 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL30001283 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL29770796 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL29827202 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL5742486 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL29827014 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL12276853 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL5728974 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL20633608 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3NR1H2GPR119 | |
| SCHEMBL12274909 | 1.00 | CHRM2 (0.46) | CHRM2CHRM1CHRM3NR1H2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517708-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2005-03-30 | — | — | EP | claimed |
| WO-2004000355-A1 | COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-12-31 | — | — | WO | claimed |
| EP-4288426-B1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12447153-B2 | HER2 mutation inhibitors | PFIZER INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250127907-A1 | PARP INHIBITORS | Stablix, Inc. | 2025-04-24 | — | — | US | disclosed |
| WO-2025054368-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NICO THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| CN-115135642-B | Inhibitors of EGFR mutant forms | 缆图药品公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-119431366-A | IRAK4 degradation agent compound and application thereof | 江苏先声药业有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20250026736-A1 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | NOVARTIS AG (CH) | 2025-01-23 | — | — | US | disclosed |
| WO-2024264072-A2 | PARP INHIBITORS | Stablix, Inc. (US) | 2024-12-26 | — | — | WO | disclosed |
| EP-0937069-B1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORP (US) | 2006-05-03 | — | — | EP | disclosed |
| EP-0900204-A4 | HETEROCYCLIC COMPOUNDS | LILLY CO ELI (US) | 2001-03-21 | — | — | EP | disclosed |
| US-6124312-A | ACTIVE DRUG FOR TREATING ALZHEIMER'S DISEASE | ELI LILLY AND COMPANY (US) | 2000-09-26 | — | — | US | disclosed |
| US-6051575-A | RESPIRATORY SYSTEM DISORDERS; SKIN DISORDERS; ANTIINFLAMMATORY AGENTS | SCHERING CORPORATION (US) | 2000-04-18 | — | — | US | disclosed |
| US-5968929-A | USEFUL IN THE TREATMENT OF CHRONIC AIRWAY DISEASES SUCH AS ASTHMA | SCHERING CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| EP-0937069-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1999-08-25 | — | — | EP | disclosed |
| EP-0900204-A1 | HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-03-10 | — | — | EP | disclosed |
| WO-1998018788-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1998-05-07 | — | — | WO | disclosed |
| WO-1997040016-A1 | HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026736-A1 | 3-(5-oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives and Uses thereof | HBZ, HBG1, HBG2 | CHRM2 4722/4885CHRM1 4635/4885CHRM3 4631/4885 |
| US-12447153-B2 | HER2 mutation inhibitors | ERBB2, EGFR, ERBB3 | CHRM2 2009/4885CHRM1 1931/4885CHRM3 3801/4885 |
| US-20250127907-A1 | PARP INHIBITORS | PARP1, PARP2, PARP3 | CHRM2 4885/4885CHRM1 4884/4885CHRM3 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.